Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
暂无分享,去创建一个
V. A. Stewart | Marie-Claude Dubois | In-Kyu Yoon | W. Ballou | Joe D. Cohen | C. Ockenhouse | W. Ballou | K. Kester | Christine Prosperi | I. Yoon | D. Lanar | B. Giersing | M. Dowler | D. Heppner | K. Tucker | F. Dubovsky | Christian F Ockenhouse | Elissa Malkin | Filip Dubovsky | Collette J. Hillier | Kent E Kester | D Gray Heppner | Urszula Krzych | W Ripley Ballou | Michele D Spring | J. Cummings | James F Cummings | Kathryn Tucker | V Ann Stewart | Mark E Polhemus | B Ted Hall | Robert J Schwenk | M. Dubois | David E Lanar | Douglas S Walsh | Christine Prosperi | Laure Y Juompan | Lisa A Ware | Jack Williams | Megan Dowler | Robin K Nielsen | Collette J Hillier | Birgitte K Giersing | Joe D Cohen | U. Krzych | D. Walsh | R. Schwenk | M. Polhemus | L. Ware | B. T. Hall | Jack L. Williams | L. Juompan | R. Nielsen | Elissa Malkin | B. Hall | Joe D. Cohen | Douglas S. Walsh | Michele D. Spring | B. Ted Hall | D. Gray Heppner Jr | Mark E. Polhemus
[1] S Walters,et al. T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic , 1997, Infection and immunity.
[2] V. Appay,et al. Phenotype and function of human T lymphocyte subsets: Consensus and issues , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[3] B. Lell,et al. Parasite antigen-specific interleukin-10 and antibody reponses predict accelerated parasite clearance in Plasmodium falciparum malaria. , 1999, European cytokine network.
[4] G. Leroux-Roels,et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. , 2008, Vaccine.
[5] M. Alpers,et al. Sequence variations in the non-repetitive regions of the liver stage-specific antigen-1 (LSA-1) of Plasmodium falciparum from field isolates. , 1995, Molecular and biochemical parasitology (Print).
[6] F. Migot-Nabias,et al. Factors influencing resistance to reinfection with Plasmodium falciparum. , 1999, The American journal of tropical medicine and hygiene.
[7] J. Kurtis,et al. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. , 2001, Trends in parasitology.
[8] L. BenMohamed,et al. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. , 1994, Journal of immunology.
[9] J. Harty,et al. CD8+ T cell contraction is controlled by early inflammation , 2004, Nature Immunology.
[10] U. Krzych,et al. The dissection of CD8 T cells during liver-stage infection. , 2005, Current topics in microbiology and immunology.
[11] Mario Roederer,et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.
[12] M. Aidoo,et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria , 1992, Nature.
[13] B. Lell,et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. , 1999, The Journal of infectious diseases.
[14] W. Ripley Ballou,et al. Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ1 , 2003, The Journal of Immunology.
[15] S. Hoffman,et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. , 1998, The Journal of infectious diseases.
[16] L. Rénia,et al. Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. , 1993, Journal of immunology.
[17] S. Hoffman,et al. Boosting of DNA Vaccine-Elicited Gamma Interferon Responses in Humans by Exposure to Malaria Parasites , 2005, Infection and Immunity.
[18] I. Schneider,et al. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. , 1995, Journal of immunology.
[19] V. A. Stewart,et al. Preclinical Evaluation of the Safety and Immunogenicity of a Vaccine Consisting of Plasmodium falciparum Liver-Stage Antigen 1 with Adjuvant AS01B Administered Alone or Concurrently with the RTS,S/AS01B Vaccine in Rhesus Primates , 2007, Infection and Immunity.
[20] Purnomo,et al. Assessment of age-dependent immunity to malaria in transmigrants. , 1997, The American journal of tropical medicine and hygiene.
[21] L. Rénia,et al. In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[22] E. Angov,et al. Process Development and Analysis of Liver-Stage Antigen 1, a Preerythrocyte-Stage Protein-Based Vaccine for Plasmodium falciparum , 2005, Infection and Immunity.
[23] J. Stephenson,et al. Defective adenoviruses as novel vaccines for the Flaviviridae. , 1998, Clinical and diagnostic virology.
[24] V. A. Stewart,et al. Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone , 2007, Infection and Immunity.
[25] V. A. Stewart,et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.
[26] D. Webster,et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans , 2003, Nature Medicine.
[27] M. Demoitié,et al. Murine Immune Responses to Liver-Stage Antigen 1 Protein FMP011, a Malaria Vaccine Candidate, Delivered with Adjuvant AS01B or AS02A , 2006, Infection and Immunity.
[28] C. Atkinson,et al. Non-CS pre-erythrocytic protective antigens. , 1990, Immunology letters.
[29] J. Kurtis,et al. Interleukin-10 Responses to Liver-Stage Antigen 1 Predict Human Resistance to Plasmodium falciparum , 1999, Infection and Immunity.
[30] S. Hoffman,et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. , 1986, The American journal of tropical medicine and hygiene.
[31] J. Barnwell,et al. Aotus nancymaae as a potential model for the testing of anti-sporozoite and liver stage vaccines against Plasmodium falciparum. , 2006, The American journal of tropical medicine and hygiene.
[32] G. Trinchieri,et al. Interleukin-10 production by effector T cells: Th1 cells show self control , 2007, The Journal of experimental medicine.
[33] C. John,et al. Gamma Interferon Responses to Plasmodium falciparum Liver-Stage Antigen 1 and Thrombospondin-Related Adhesive Protein and Their Relationship to Age, Transmission Intensity, and Protection against Malaria , 2004, Infection and Immunity.
[34] M. Demoitié,et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. , 2008, Vaccine.
[35] G. Weverling,et al. Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1 , 2008, Infection and Immunity.